Comparison of the clinical effects of two different doses (0.05% and 0.1%) of topical cyclosporine A in dry eyes with meibomian gland dysfunction
ABSTRACT Objective: To compare the clinical efficacy of two different doses of topical cyclosporine A used in addition to artificial tears in the treatment of patients with meibomian dysfunction and secondary dry eye. Methods: Fifty patients aged 18 to 40 years, who presented to our clinic between...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sociedade Brasileira de Oftalmologia
2022-06-01
|
| Series: | Revista Brasileira de Oftalmologia |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0034-72802022000100221&lng=en&tlng=en |
| _version_ | 1829104726776479744 |
|---|---|
| author | Kemal Bayrakceken Adem Ugurlu |
| author_facet | Kemal Bayrakceken Adem Ugurlu |
| author_sort | Kemal Bayrakceken |
| collection | DOAJ |
| description | ABSTRACT Objective: To compare the clinical efficacy of two different doses of topical cyclosporine A used in addition to artificial tears in the treatment of patients with meibomian dysfunction and secondary dry eye. Methods: Fifty patients aged 18 to 40 years, who presented to our clinic between June 2020 and June 2021 were included in our study. Patients were divided into two groups as Group A (topical cyclosporine A 0.05%) and Group B (topical cyclosporine A 0.1%). All the patients underwent a detailed ophthalmological examination, basal Ocular Surface Disease Index measurement, and Schirmer 1 and tear break-up time tests at all visits. Results: The mean age was 32±7.1 years in Group A and 30.7±8.5 years in Group B. In Group A, there were 15 women and ten men, and Group B consisted of 14 women and 11 men. There was no difference between the groups in terms of age and gender distribution (p>0.05). Schirmer 1 and tear break-up time results and Ocular Surface Disease Index score also did not significantly differ between the groups (p>0.05). Conclusion: Cyclosporine A 0.05% and 0.1% eye drops were both seen to be effective in managing dry eye disease in patients with meibomian gland dysfunction. |
| first_indexed | 2024-12-12T05:53:40Z |
| format | Article |
| id | doaj.art-2b031816153a45e98970be0aaccf5758 |
| institution | Directory Open Access Journal |
| issn | 1982-8551 |
| language | English |
| last_indexed | 2024-12-12T05:53:40Z |
| publishDate | 2022-06-01 |
| publisher | Sociedade Brasileira de Oftalmologia |
| record_format | Article |
| series | Revista Brasileira de Oftalmologia |
| spelling | doaj.art-2b031816153a45e98970be0aaccf57582022-12-22T00:35:37ZengSociedade Brasileira de OftalmologiaRevista Brasileira de Oftalmologia1982-85512022-06-018110.37039/1982.8551.20220044Comparison of the clinical effects of two different doses (0.05% and 0.1%) of topical cyclosporine A in dry eyes with meibomian gland dysfunctionKemal Bayrakcekenhttps://orcid.org/0000-0001-9550-1358Adem Ugurluhttps://orcid.org/0000-0002-8900-7043ABSTRACT Objective: To compare the clinical efficacy of two different doses of topical cyclosporine A used in addition to artificial tears in the treatment of patients with meibomian dysfunction and secondary dry eye. Methods: Fifty patients aged 18 to 40 years, who presented to our clinic between June 2020 and June 2021 were included in our study. Patients were divided into two groups as Group A (topical cyclosporine A 0.05%) and Group B (topical cyclosporine A 0.1%). All the patients underwent a detailed ophthalmological examination, basal Ocular Surface Disease Index measurement, and Schirmer 1 and tear break-up time tests at all visits. Results: The mean age was 32±7.1 years in Group A and 30.7±8.5 years in Group B. In Group A, there were 15 women and ten men, and Group B consisted of 14 women and 11 men. There was no difference between the groups in terms of age and gender distribution (p>0.05). Schirmer 1 and tear break-up time results and Ocular Surface Disease Index score also did not significantly differ between the groups (p>0.05). Conclusion: Cyclosporine A 0.05% and 0.1% eye drops were both seen to be effective in managing dry eye disease in patients with meibomian gland dysfunction.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0034-72802022000100221&lng=en&tlng=enCyclosporineDry eye syndromeTear function test |
| spellingShingle | Kemal Bayrakceken Adem Ugurlu Comparison of the clinical effects of two different doses (0.05% and 0.1%) of topical cyclosporine A in dry eyes with meibomian gland dysfunction Revista Brasileira de Oftalmologia Cyclosporine Dry eye syndrome Tear function test |
| title | Comparison of the clinical effects of two different doses (0.05% and 0.1%) of topical cyclosporine A in dry eyes with meibomian gland dysfunction |
| title_full | Comparison of the clinical effects of two different doses (0.05% and 0.1%) of topical cyclosporine A in dry eyes with meibomian gland dysfunction |
| title_fullStr | Comparison of the clinical effects of two different doses (0.05% and 0.1%) of topical cyclosporine A in dry eyes with meibomian gland dysfunction |
| title_full_unstemmed | Comparison of the clinical effects of two different doses (0.05% and 0.1%) of topical cyclosporine A in dry eyes with meibomian gland dysfunction |
| title_short | Comparison of the clinical effects of two different doses (0.05% and 0.1%) of topical cyclosporine A in dry eyes with meibomian gland dysfunction |
| title_sort | comparison of the clinical effects of two different doses 0 05 and 0 1 of topical cyclosporine a in dry eyes with meibomian gland dysfunction |
| topic | Cyclosporine Dry eye syndrome Tear function test |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0034-72802022000100221&lng=en&tlng=en |
| work_keys_str_mv | AT kemalbayrakceken comparisonoftheclinicaleffectsoftwodifferentdoses005and01oftopicalcyclosporineaindryeyeswithmeibomianglanddysfunction AT ademugurlu comparisonoftheclinicaleffectsoftwodifferentdoses005and01oftopicalcyclosporineaindryeyeswithmeibomianglanddysfunction |